WP
STOK icon

Woodline Partners’s Stoke Therapeutics STOK Stock Holding History

Woodline Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Hold
50,120
– – 0.01% 856
2026
Q1 		$1.63M Hold
50,120
– – 0.01% 826
2025
Q4 		$1.59M Sell
50,120
-45,000
-47% -$1.35M 0.01% 800
2025
Q3 		$2.24M Hold
95,120
– – 0.01% 716
2025
Q2 		$1.08M Hold
95,120
– – 0.01% 797
2025
Q1 		$633K Buy
95,120
+217
+0.2% +$2.02K ﹤0.01% 810
2024
Q4 		$1.05M Buy
94,903
+521
+0.6% +$6.4K 0.01% 751
2024
Q3 		$1.16M Sell
94,382
-5,800
-6% -$82.2K 0.01% 501
2024
Q2 		$1.35M Sell
100,182
-6,722
-6% -$90.8K 0.01% 444
2024
Q1 		$1.44M Buy
106,904
+50,000
+88% +$303K 0.01% 445
2023
Q4 		$299K Hold
56,904
– – ﹤0.01% 445
2023
Q3 		$224K Sell
56,904
-40,120
-41% -$264K ﹤0.01% 549
2023
Q2 		$1.03M Hold
97,024
– – 0.01% 484
2023
Q1 		$808K Buy
+97,024
New +$875K 0.01% 489

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's STOK Position: Q2 2026 in Review

Woodline Partners held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 50,120 shares worth $1.64M. The position accounts for 0.01% of the portfolio, ranked #856.

Woodline Partners first reported a position in STOK in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.24M in Q3 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Woodline Partners held 50,120 shares of Stoke Therapeutics worth $1.64M as of Q2 2026.
  • Woodline Partners left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #856 holding.
  • Woodline Partners first reported a position in Stoke Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Woodline Partners's Stoke Therapeutics position peaked at $2.24M in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.